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Riassunto: la febbre della Rift Valley (RVF) è una arbovirosi emergente che 
colpisce ruminanti, camelidi e umani, diffusa nei paesi dell'Africa subsahariana, 
Egitto e nella penisola arabica [Anyamba et al. 2009, Gerdes 2004]. La malattia è 
causata dal virus della valle del Rift (RVFV) appartenente alla famiglia 
Bunyaviridae e al genere Phlebovirus [Ikegami et al. 2011]. I focolai nei ruminanti 
si caratterizzano per la comparsa di numerosi aborti e alta mortalità neonatale,  
mentre nei soggetti adulti non in gravidanza l'infezione può essere asintomatica 
o presentarsi con febbre, linfoadenite, congiuntivite, scolo nasale, diarrea spesso 
emorragica, ittero ed epatite [Gerdes 2004 Davies et al. 2006]. L'infezione da 
RVFV negli esseri umani provoca di solito una malattia simil-influenzale, tuttavia,  
in un numero limitato di casi si possono osservare epatite acuta, ittero, 
insufficienza renale, sindrome emorragica e disturbi neurologici [Adam et al.  
2010 Mansfield et al. 2015]. Analizzando la letteratura, abbiamo aggiornato la  
situazione epidemiologica della RVF, le misure di prevenzione e controllo e 
valutato il rischio di introduzione del virus in Europa.
Parole chiave: febbre della valle del Rift, zoonosi virali trasmesse da zanzare, 
malattie virali transfrontaliere.
Abstract: Rift Valley fever (RVF) is an arthropod-borne viral zoonotic disease of 
ruminants, camels and humans, distributed in sub-Saharan African countries, 
Egypt and the Arabian Peninsula [Anyamba et al. 2009, Gerdes 2004]. The 
disease is caused by the Rift Valley fever virus (RVFV) belonging to the family 
Bunyaviridae and the genus Phlebovirus [Ikegami et al. 2011]. 
In animals, RVF may be asymptomatic in non-pregnant adults. Outbreaks are 
characterised by the onset of abortions storms and high neonatal mortality. Older  
animals can present hight fever, lymphadenitis, nasal and ocular discharges,  
diarrhoea often haemorrhagic, jaundice and hepatitis [Gerdes 2004, Davies et al. 
2006]. RVFV infection in humans usually causes a self-limiting, acute and febrile 
illness; however, a small number of patients may present acute hepatitis,  
jaundice, renal failure, haemorrhagic syndrome and neurological disorders 
[Adam et al. 2010, Mansfield et al. 2015]. Based on a literature review, we have 
updated the RVF epidemiological situation, the measures of prevention and 
control and evaluated the risk of RVFV entering into Europe.
Keywords: Rift Valley fever; mosquito-borne viral zoonosis, viral transboundary 
diseases.
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1. Introduction
Arboviruses (arthropod-borne viruses) are transmitted to animals and humans 
by the bite of insects. During the past 20 years there has been a dramatic 
resurgence or emergence of epidemic arboviral diseases affecting both 
humans and domestic animals [Gubler 2002].
Rift Valley Fever (RVF) is a mosquito-borne viral zoonosis widespread in 
humans and ruminants in Africa and Arabian Peninsula [Nanyingi et al. 2015]. 
The disease is caused by RVF virus (RVFV), belonging to the Bunyaviridae 
family and Phlebovirus genus, which has been isolated from more than 30 
mosquito species [Ikegami et al. 2011].
The main mosquito vectors belongs to the genus Aedes and Culex. 
RVFV can also be transmitted to humans through direct contact with blood or 
contaminated organs and biological fluids and therefore it is considered an 
occupational disease affecting veterinarians, animal handlers and abattoir  
workers [Paweska 2015].
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Figure 1: Dodoma, shepherds on the street.
RVF is listed by the World Organisation for Animal Health in the category of 
multiple species diseases. The overall importance of RVF depends on the 
disease impact on human health, animal production and animal welfare and is  
one of the priority diseases of FAO Emergency Prevention System. 
The aim of this thesis is to update RVF epidemiological situation, sanitary 
measures of prevention and control and to evaluate the risk of RVFV entering 
into Europe.
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Figure 2: RVF occurrence in the periods  
(a) 1993–1999, (b) 2000–2005, (c)  
2006–2012 [EFSA 2013].
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2. History and geographical distribution
The first suspected case in sheep was observed in 1912, but the disease was 
described in sheep, cattle, and humans and the virus isolated in 1931 in 
Kenya, near the Lake Naivasha in the Rift Valley [Daubney et al. 1931]. In the 
same Country a major epizootic occurred during the years 1950-51, which 
resulted in 500,000 sheep abortions and 100,000 sheep deaths. In the 
following years the disease was also detected in South Africa. 
In 1977-78, an outbreak of RVF occurred along the Nile in Egypt. This 
outbreak resulted in an estimated 200,000 affected humans and 598 human 
deaths following encephalitis and haemorrhagic fever. During this outbreak the 
virus affected millions of ruminants and many abortions and deaths were 
reported in sheep, goats, cattle, water buffalo and camels. This  outbreak 
occurred six years after completion of the Aswan dam, which had created large 
flood-lands and increased the breeding habitat of competent mosquito species.
In 1987, an outbreak of RVF occurred in the Senegal river basin (West Africa) 
just one year after the construction of the Diama dam along the Senegal River . 
While previous RVF outbreaks were typically associated with heavy rainfall, 
this outbreak in Senegal followed the high rate of reproduction of vectors 
occurring along the river and dam [Swanepoel et al. 2004].
Outbreaks of RVF in animals and humans occurred again in Kenya during 
years 1997-1998. 
The first confirmed outbreaks of RVF outside Africa occurred in Saudi Arabia 
from August 2000 to September 2001.
Outbreaks of RVF occurred again in Egypt in August of 2003 in a rural region 
located 150 kilometres north of Cairo.
In 2006 RVF was again detected in Kenya, spreading to the surrounding 
countries of Tanzania and Somalia. Over 1000 human cases were reported 
with case-fatality rates ranging from 23% to 45%. The epidemic was controlled 
by restrictions in animal movements, stamping out and by vaccination of 
livestock.
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During 2010, over 14,000 cases of RVF in animals were detected in South 
Africa [WHO 2007, Nanyingi et al. 2015, FAO 2015].
In the lasts years RVF was recorded in the following countries: 
• Senegal (2013):  8 cases and 3 deaths in Gazella dorcas (Bovidae),
 37 cases and 8 deaths in goats [OIE report 2013].
• Senegal (2014): 7 cases without any deaths in cattle [OIE report 2014].
• Botswana (2014): 2 cases without deaths in cattle [OIE report 2014]. 
• Mauritania (2015): four outbreaks in sheep and goat with 19 cases and 
19 destroyed animals and 25 human cases with 8 deaths [Pittiglio et al.  
2015, OIE report 2015].
• Uganda (2016): 5 human cases and 1 case in goat [OIE report 2016].
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Table 1: Main outbreaks from 1931 until 2016 [Nanyingi et al. 2015, modified].
Year(s) Country Animals 
cases
Animals 
deaths
Humans 
cases
Humans 
deaths 
1931 Kenya nd 4,700 nd nd
1950-1951 Kenya² 500,000 100,000 nd nd
South Africa 600.000 100,000 nd nd
1977-1978 Egypt nd nd 200,000 598
1978 Zimbabwe 70,000 10,000 nd nd
1988 Mauritania nd nd nd 224
1987-1989 Senegal 1,715 nd 273 16
1997-1998 Kenya 89,000 478 160,000 478
Somalia nd nd 28,000 170
Tanzania nd nd 89,000 478
1998 Mauritania 343 nd 90 1
2000 Saudi Arabia >10,000 1,000 883 245
2000-2001 Yemen 22,000 6,000 1,328 166
2003 Egypt nd nd 45 17
2006-2007 Kenya nd nd 75,000¹ (684) 158
Tanzania 32,000 4,200 40,000¹ (264) 109
Somalia nd nd 35,000¹ (114) 51
2007-2008 Sudan nd nd 75,000¹ (698) 222
2008-2009 Madagascar nd nd 10,000¹ (712) 26
2010³ Mauritania nd nd 63 13
2010-2011 South Africa 14,342 8,877 242 26
2012 Mauritania nd 343 41 17
20134 Senegal 45 11 nd nd
20144 Botswana 2 0 nd nd
2015 4 5 Mauritania 19 196 25 8
20164 Uganda 1 0 5 nd
nd: not determined; 
¹ Estimated cases (in brackets the reported cases).
² [FAO 2015].
³ [El Mamy et al. 2011].
4 [OIE reports ].
5 [Pittiglio et al. 2015].
6 destroyed animals.
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Figure 3: spatial and temporal distribution of RVF. Total number of human deaths  
(HD) is indicated for countries [Nanyingi et al. 2015]. 
The disease in humans and domestic ruminants has been also reported in the 
following other countries: Zambia, Malawi, Nigeria, Mozambique, Zaire (Congo 
Democratic Republic), Central African Republic, Ethiopia. Specific antibodies 
to RVFV, without evidence of disease, were detected in ruminants of other 
African countries: Mali, Gambia, Cameroon, Chad, Guinea, Burkina Faso, 
Niger, Angola, Côte d’Ivoire (Fig.4) [Nanyingi et al. 2015].
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Figure 4: map of RVF geographical distribution until 2014 [Centers  
for Disease Control, CDC].
3. Aetiology.
The Bunyaviridae is a large family of viruses and contains five genera, four of 
which infect vertebrates, while the remaining genus, Tospovirus, contains a 
group of plant viruses. Three of the vertebrate-infecting genera, Bunyavirus, 
Phlebovirus and Nairovirus are associated with arthropods, while the last 
genus, Hantavirus, has no known invertebrate association.
Rift Valley fever virus is a member of the genus Phlebovirus [Gerdes 2004]. 
The viral particles have a spherical shape, with a diameter of 80 - 120nm and 
are surrounded by the envelope. RVFV genome (Fig 5) is composed of three 
segments (large, medium and small) of single-stranded, negative-sense RNA, 
with the exception of the small segment that consist of ambisense RNA with a 
bidirectional coding. Replication occurs in the cytoplasm of the infected cells 
[Won et al. 2007, Pepin et al. 2010, Mansfield et al. 2015].
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Figure 5: the RVFV virion and genome structure, with small (S), medium (M) and  
large (L) segments in linear representation [FAO 2015].
Virus resistance to physical and chemical action is as follows: 
- temperature: the virus is still alive in serum after several months at 4°C and 
is inactivated at 56°C and by pasteurisation;
- pH: RVFV is resistant in alkaline environments but rapidly inactivated at pH 
<6.8;
- chemicals/disinfectants: the virus is inactivated by lipid solvents (i.e. ether, 
chloroform, sodium deoxycholate), low concentrations of formalin and strong 
solutions of sodium or calcium hypochlorite (residual chlorine should exceed 
5000 ppm),  but it can survive if put in contact with 0.5% phenol solution at 
4°C for 6 months;
- the virus can survive in aerosols at 23°C with 50%–85% humidity and in the 
eggs of mosquito vectors during inter-epidemic periods [Mims et al.1956].
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Figure 6:  Electron micrograph of the RVFV.
RVFV is dispersed over an extensive geographic area and infects a wide 
range of arthropod vectors and vertebrate hosts [Grobbelaar et al 2011]. No 
significant antigenic differences have been demonstrated among RVFV strains 
isolated in various countries, but differences in pathogenicity among 
genotypes have been shown [Bird et al., 2007, Swanepoel et al. 1986]. The 
existence of only one serotype and the high degree of conservation of genes 
encoding for the surface glycoproteins indicate that a single vaccine would 
protect against all circulating viral strains. The high preservation of the RNA-
dependent RNA polymerase gene sequence implies that antiviral drugs will  
inhibit replication of all known genetic lineages of the virus [Paweska et al 
2015]
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3.1 Host range.
The vertebrate host range is quite wide involving several mammalian 
species. Domesticated ruminants are the primary species affected and likely 
the major amplifiers of the virus [ Paweska 2015 ].
However, susceptibility varies depending on the host species and breed and 
there is a clearly increased level of resistance to RVF infection with age  [Zhao 
et al. 2008, Pepin et al. 2010].
Exotic sheep and cattle are less resistant to RVF than indigenous African 
livestock [Davies et al. 1981].
Lambs, kids, puppies, kittens, mice, hamsters and young laboratory rodents 
are extremely susceptible (70% - 100% mortality). Sheep and calves are 
highly susceptible (20% - 70% mortality). Cattle, goats, camels, buffalos, 
some wild antelopes, equids, pigs, rabbits, dogs and cats may develop a 
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Table 2: Susceptibility of vertebrates to RVFV [EFSA 2005].
transient viraemia and antibody to RVFV, without signs of disease,  following 
experimental or field infections (Tab.2). Laboratory studies have shown that 
many other species, as woodmice, voles, dormice, lauchas, gerbils and 
squirrels may develop viraemia, without clinical signs. Birds, reptiles, 
amphibians are not susceptible at all [Daubney et al. 1931,  Easterday et al. 
1962, Easterday et al. 1963, Swanepoel 1976, Davies et al. 1978].
Monkeys and humans are moderately susceptible (mortality less than 10%), 
but humans can develop sufficient viraemia to be a source of infection for 
mosquitoes, contributing to the spread of the virus [Paweska 2015 ].
Many African wildlife species tested positive for antibody against RVFV, 
including: topi (Damaliscus korrigum); red-fronted gazelle (Eudorcas 
rufifrons); dama gazelle (Nanger dama); scimitar-horned oryx (Oryx 
dammah); common reedbuck (Redunca redunca); African buffalo (Syncerus 
caffer); Dorcas gazelle (Gazella dorcas); Thomson’s gazelle (Gazella  
thomsonii); gerenuk (Litocranius walleri); lesser kudu (Tragelaphus 
strepsiceros); impala (Aepyceros melampus); sable antelope (Hippotragus 
niger); waterbuck (Kobus ellipsiprymnus); warthog (Phacochoerus 
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Figure 7: Orma Boran cattle crossing a river in Kenya  
(photo credit: ILRI/Rosemary Dolan).
aethiopicus); African bush elephant (Loxodonta africana); giraffe (Giraffa 
camelopardalis); Burchell’s zebra (Equus burchellii); and black rhinoceros 
(Diceros bicornis). Although serological evidence suggests that a large 
number of African wildlife species might play a role in the epidemiology of 
RVF, their possible role in the maintenance of the virus is poorly understood 
[Olive et al. 2012, Britch et al. 2013, Paweska 2015 ].
RVF outbreaks in 2013 in Senegal, confirm the importance of wildlife species 
in the epidemiology of RVF, with 8 cases and 3 deaths in the species Gazella 
dorcas and two outbreaks in domestic ruminant [OIE report 2013].
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Figure 9:Gazella dorcas.
Figure 8: African buffalo, Syncerus caffer.
4. Epidemiology
4.1 Vectors
RVF is essentially a vector transmitted disease and in the first stage of 
epizootics, the bites of infected mosquitoes are the predominant mode of 
transmission [Morrill et al. 1996].
Vectors of RVFV can be classified into ‘‘reservoir/maintenance’’ vectors, 
including certain Aedes species (spp.) and ‘‘epidemic/amplifying’’ vectors, 
consisting of Culex spp. [McIntosh et al. 1983, Swanepoel et al. 2011].
Table 3 and Table 4 provide a nearly complete record of natural and 
experimental susceptibility and vector competence of mosquito vectors. Also 
included are some of the other species of arthropods that could be involved 
as mechanical vectors.
Table 3: Arthropods infected with RVFV in nature [EFSA 2005].
Genus (Subgenus) Species Locality (year)
Aedes 
(Aedimorphus)
cumminsii Kenya (1981-84)
Burkina Faso (1983)
dalzieli Senegal (1974, 1983)
dentatus Zimbabwe (1969)
durbanensis Kenya (1937)
ochraceus Senegal (1993)
tarsalis Uganda (1944)
vexans arabiensis Senegal (1993)
Saudi Arabia (2000)
Aedes 
(Neomelaniconion)
circumluteolus Uganda (1955)
South Africa (1955, 1981)
mcintoshi Zimbabwe (1969)
South Africa (1974-75)
Kenya (1981-84)
palpalis Central African Republic 
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(1969)
Ochlerotatus ¹
(Ochlerotatus)
caballus South Africa (1953)
caspius² Egypt, suspected (1993)
juppi South Africa (1974-75)
Aedes (Stegomyia) africanus Uganda (1956)
demeilloni/dendrophilus Uganda (1944)
Aedes (Diceromyia) furcifer group³ Burkina Faso (1983)
Anopheles
(Anopheles)
coustani Zimbabwe (1969)
Madagascar (1979)
fuscicolor Madagascar (1979)
Anopheles (Cellia) christyi Kenya (1981-84)
cinereus South Africa (1974-75)
pauliani Madagascar (1979)
pharoensis Kenya (1981-84)
squamosus Madagascar (1979)
Culex (Culex) spp.4 Madagascar (1979)
antennatus Nigeria (1967-70)
Kenya (1981-84)
neavei South Africa (1981)
pipiens Egypt (1977, 1978)
poicilipes Senegal (1998)
theileri South Africa (1970)
Zimbabwe (1969)
tritaeniorhynchus Saudi Arabia (2000)
vansomereni Kenya (1981-84)
zombaensis South Africa (1981)
Kenya (1981-84, 1989)
Culex
(Eumelanomyia)
rubinotus Kenya (1981-84)
Eretmapodites chrysogaster Uganda (1944)
quinquevittatus South Africa (1971)
Kenya (1981-84)
Coquillettidia
(Coquillettidia)
fuscopennata Uganda (1959)
grandidieri Madagascar (1979)
Mansonia africana Uganda (1959, 1968)
Central African Republic 
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(Mansoniodes) (1969)
Kenya (1989)
uniformis Uganda (1959)
Madagascar (1979)
Other Diptera Culicoides spp. Nigeria (1967)
1 Former subgenus of Aedes, recently elevated to generic rank
2 Suspected due to being the predominant mosquito species during the outbreak, vector competence 
confirmed in the laboratory.
3 Representing a species complex consisting of 3 possible species, Ae. furcifer, Ae. cordellieri & Ae. 
taylori.
4 Culex spp. may include annulioris, antennatus, simpsoni & vansomereni.
Table 4: Arthropods species which have demonstrated vector competence in the  
laboratory [EFSA 2005].
Genus (Subgenus) Species Mode of transmission
Aedes (Aedimorphus) fowleri biological
Aedes(Neomelaniconion) circumluteolus biological
macintoshi biological
Aedes (Protomacleaya) triseriatus biological
Aedes (Stegomyia) aegypti biological, mechanical
aegypti formosus mechanical
albopictus biological
Ochlerotatus (Finlaya) notoscriptus biological
Ochlerotatus 
(Ochlerotatus)
caballus biological
canadensis biological
cantator biological
caspius biological
excrucians biological
juppi biological
sollicitans biological
taeniorhynchus biological, mechanical
vigilax biological
Anopheles (Cellia) multicolor biological
pharoensis biological
Coquillettidia 
(Coquillettidia)
versicolor biological
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Culex (Culex) annulirostris biological
antennatus biological
neavei biological
perexiguus biological
pipiens biological, mechanical
poicilipes biological
quinquefasciatus biological
salinarius biological
tarsalis biological
theileri biological
univittatus biological
zombaensis biological
Culex (Neoculex) territans biological
Eretmapodites chrysogaster biological
quinquevittatus biological
Other Diptera Stomoxys calcitrans mechanical
Glossina morsitans mechanical
Lutzomyia longipalpis mechanical
Phlebotomus dubosqi mechanical
Culicoides variipennis mechanical
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Figure 10: Aedes mcintoshi  
[http://www.mosquitocatalog.org/ta
xon_descr.aspx?ID=18159]
Several potential RVFV vectors are present in Europe (Tab. 5). 
The introduction of other competent mosquito vectors, as a consequence of  
climate changes, may represents a further risk for the RVFV entering in 
Europe.
Table 5: presence in Europe of mosquito vectors competent for RVFV  
[EFSA 2005, modified].
Country Aedes 
vexans 
vexans
Ochlerotatus 
caspius s.l.
Culex 
theileri
Culex 
pipiens
Culex 
perexiguus/
univittatus
Aedes 
albopictus¹
Albania x x x
Austria x x x
Belarus x x x x
Belgium x x x
Bosnia-
Herzegovina
x x
Bulgaria x x x x x
Croatia x x x x
Cyprus x x
Czech 
Republic
x x x
Denmark x x x
Estonia x x x
European 
Russia
x x x x
Finland x x x
France x x x x x
Germany x x x x
Greece x x x x x x
Hungary x x x x
Ireland x x
Italy x x x x x x
Italy: x x x x x
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Sardinia
Latvia x x x
Lithuania x x x
Luxembourg
Macedonia x x x x x
Malta x x
Moldova x x x
Norway x x
Poland x x x
Portugal x x x x x
Romania x x x x
Serbia and 
Montenegro
x x x x
Slovakia x x x x
Slovenia x x x x
Spain x x x x x x
Spain: 
Balearic 
Islands
x x
Sweden x x x
Switzerland x x x
The 
Netherlands
x x x
Turkey x x x x x
Ukraine x x x x
United 
Kingdom
x x x
¹ [Rodhain 1995, Moutailler et al. 2007, ECDC 2008]
X: vector present
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4.2 RVF ecosystems.
RVF has been reported in four ecological systems: dambo areas, semi-arid 
areas, irrigated areas and temperate and mountainous areas.
The word “dambo” indicates grasslands with shallow depressions often 
located near rivers, which fill with water during the rainy season. In dambo 
areas, a correlation between heavy rainfall and RVF epidemics has been 
demonstrated [Linthicum et al., 1999]. In this ecosystems it's possible the 
transmission from one mosquito generation to another, (vertical transmission)  
in Aedes (Neomelaniconion) mcintoshi. In addition, the virus may survive in 
Aedes eggs which are resistant to desiccation over a long period of time, 
during inter-epidemic periods [Linthicum et al. 1985].
Semi-arid areas, in which RVF has been reported, are characterised by 
temporary water points, such as found in northern Senegal and Mauritania. In  
these areas, the mechanism of virus persistence remains unclear. It could be 
related to the vertical transmission of the virus in Aedes mosquitoes or in 
alternative could be related with regular introduction of the virus by nomadic 
30
Figure 11: entomologists collecting mosquito  
vectors for laboratory analysis in a dambo  
area, Kenya [USDA, Agricultural Research  
Service].
herds coming from neighbouring endemic areas. These possibilities are not  
mutually exclusive [Chevalier et al. 2005].
Irrigated areas where RVF occurs include the Nile Delta (Egypt) and the 
Senegal River valley (Senegal, Mauritania), where abundance of permanent 
water enhance the development of Culex populations and viral transmission 
[Meegan et al. 1979].
Temperate and mountainous areas, such as those found in Madagascar, 
enhance transmission of RVFV by local vectors associated with specific 
practices of cattle managements.
Cattle come back from field in late afternoon and spend the night in pens 
where infection by mosquito bites can occur.
Another potential risk factor is the vicinity to the forest. The existence of a 
wild cycle involving mosquitoes and wild reservoirs living in the forest could 
explain the persistence and the periodical re-emergence of the virus in these 
areas [Chevalier et al. 2011].
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Figure 12: Mauritania semi-arid areas  
[figmentsandimagination.files.wordpress.com].
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Figure 13: Madagascar temperate and mountainous  
areas, Zebù .
Figure 14: ecological cycle of RVF. [ Centers for Disease Control and Prevention  
2016]
4.3 Vectorial transmission
Vectorial transmission occurs through mosquitoes mainly of the genus Aedes 
and Culex.
The virus replicates in the cells of the midgut of the vector, is disseminated 
via the haemolymph and replicate in other organs and in the salivary glands.  
After the ingestion of the virus there is an extrinsic incubation period lasting 
one to two weeks, before transmission to vertebrate hosts can occur. High 
temperature increase vector efficiency ( higher transmission rates and shorter  
extrinsic incubation period). Transovarial vertical transmission has been 
demonstrated in mosquitoes of the genus Aedes and these are therefore 
considered “maintenance vectors” of RVFV. This gives an explanation to the 
maintenance of the virus in the absence of suitable environmental conditions 
because the eggs can survive for long periods in the dried soil and in the 
mud of dried-up surface water pools (Fig.14). [Linthicum et al. 1983, 
Linthicum et al. 1985]. 
To occur epidemics outbreak must be present environmental conditions that 
increase a massive build-up in mosquito vector populations and the presence 
of susceptible hosts. These events usually happens in presence of warm 
conditions and heavy and persistent rainfall that cause surface flooding,  
particularly in “dambos” (Fig.15), and lead to the hatching of infected Aedes 
spp. mosquito eggs (Fig.14). Flooding increase the concentration of animals 
and humans in areas of dry 
land, thus further increasing 
the potential for virus 
transmission [Linthicum et al. 
1983, Pepin et al. 2010]. 
Aedine mosquitoes are 
therefore responsible for the 
primary cycles of RVFV 
transmission. Culicine 
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Figure 15: flooded area in Kenya.
mosquitoes contribute to amplify the viral transmission to the vertebrate hosts 
during the epidemics, being responsible of secondary transmission cycles, 
but do not play any role in the maintenance of the virus during inter-epidemic 
periods [Turell 1990, Ndiaye et al. 2016].
While aedine mosquitoes tend to remain in the immediate vicinity of their  
breeding sites, Culex mosquitoes disperse widely to feed on vertebrate 
hosts.
Infected mosquitoes can also be carried to long distances by wind and RVFV 
can spread to new territories and, in presence of suitable conditions, it can 
give rise to new foci of infection [Chevalier et al. 2004]. 
Mechanical vectorial transmission has been demonstrated in laboratory 
studies by various mechanical vectors, especially larger haematophagous 
flies, e.g. Tabanidae. This kind of transmission may occur when infectious 
viral particles are attached to the mouth parts of the vector after an 
interrupted feed on a viraemic host and are re-inoculated when the insect  
resumes feeding on a second host. Due to the high viraemia, any 
haematophagous arthropods that feed on RVF viraemic animals, as 
stomoxids, simulids, phlebotomids and midges, would be able to act as 
mechanical vectors of RVFV  [Hoch et al. 1985]. 
Also in human infections can result from the bites of infected mosquitoes, 
mainly of genus Aedes [Linthicum et al. 1985]. The main vector in the 
Egyptian epizootic of 1977–1978 was the peri-domestic and anthropophilic  
mosquito Cx. Pipiens. We cannot exclude that human infection may also 
result from bites by other blood-feeding insects, such as midges, 
phlebotomids, stomoxids and simulids, acting as mechanical vectors 
[Paweska, 2015].
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4.4 Other way of transmission 
4.4.1 In animals
Body fluids, secretion and excretions of infected animals, particularly aborted 
foetal materials and placental membranes, may contaminate the 
environment, contributing to transmission in animals during the amplification 
stage of the epizootic [Morrill et al. 1996].
Infection via the oral mucosal surfaces has been documented [Easterday et 
al. 1962], although some studies show that lambs, kittens and puppies fed 
with RVFV-contaminated milk are not infected [Keefer et al. 1972]. The 
presence of the virus in milk during the viraemic phase has been confirmed 
experimentally but in later stages of infection, the presence of virus in milk is 
questionable and, if it exists, the viral load would be low [Easterday et al. 
1962].
Infection via aerosol was demonstrated, in mice and hamsters, in a study 
performed by Easterday el at. [Mims 1956, Easterday et al. 1963]. Exposure 
of animals to aerosol containing RVFV probably results in initial RVFV 
infection in lung epithelial cells [Gerrard et al. 2002].
4.4.2 In humans 
The majority of human infections result from direct or indirect contact with 
body fluids and organs of infected animals. The virus can be transmitted also 
by contact with secretions and excretions of infected animals, which may take 
place during slaughter or while handling infected animals, aborted foetuses or  
animal tissues and conducting veterinary procedures. Certain occupational 
groups such as herders, farmers, slaughterhouse workers and veterinarians 
are therefore at higher risk of infection. The virus infects humans through 
inoculation via a wound from an infected knife, contact with broken skin, 
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inhalation of aerosols produced during the slaughter of infected animals. The 
aerosol transmission can also led to infection in laboratory workers, if the 
required safety precautions are not observed [Swanepoel et al. 2011, 
Paweska 2015].
There is some evidence that humans may also become infected with RVFV 
by ingesting the unpasteurized milk of infected animals even if the virus is not 
able to withstand to pH values below 6.8 [Mims et al.1956]. 
To date, no human-to-human transmission of RVFV has been documented, 
including from patients to healthcare workers, but standard safety measure 
are highly recommended [WHO 2010].
Consumers of meat are not at risk, as the virus is rapidly inactivated at pH<6 
during processing, furthermore the meat is usually consumed after cooking 
[Swanepoel et al. 2004, 2011].
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Figure 16: milking, Kenya.
Figure 17: detailed description of the RVF transmission cycle [FAO 2012].
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5. Pathogenesis.
RVFV infects vertebrates mainly through the bite of infected mosquitoes while 
performing the blood meal. After the bite, the virus moves from the skin to 
draining lymph nodes, where it replicates. Efferent lymphatics bring the virus 
into the blood circulation to produce a primary viraemia that brings the virus to  
the target organs: liver and spleen. 
Studies of experimental subcutaneous infection of 1-4 day-old lambs with 
RVFV, indicates that hepatocytes are the primary target cells of the virus [Van 
der Lugt et al.1996]. The replication in the target organs is followed by a 
secondary viraemia during which the virus may cross the placenta to infects 
the foetus and causes abortion. Viraemia may become demonstrable in 
newborn lambs within 16 hours after infection. In older sheep, goats and cattle  
viraemia appear one to two days after infection and persist up to seven days 
with a maximum intensity peak between 2 and 5 days post infection [Coackley 
et al.1967, Davies et al. 1981]. 
In humans the virus has been demonstrated in the blood during the febrile  
period (3–4 days), whereas neutralizing antibody starts appearing around the 
4th day of the onset of symptoms [Findlay et al. 1931, Kitchen 1934, Sabin et 
al. 1947, Smithburn et al. 1949] .
Hepatic failure occurs in all species but it is most severe in extremely 
susceptible hosts, such as new-born lambs and kids. In these animals hepatic 
lesions rapidly progress to a massive necrotic hepatitis just before death. In 
less susceptible animals, such as adult sheep and goats, the hepatic lesions 
tend to be more focal in nature (Fig.18) [Swanepoel 2004].
This difference has not yet received a clear explanation but might be due to 
age-related susceptibility of young animals that allows a rapid and intense viral  
replication during early infection [Zaho et al. 2008, Pepin et al. 2010].
Cellular damage is due to the lytic effect of the virus that can be mediate by 
the host immune response.  
The virus may also cross the blood-brain barrier and infect neurons and glia. In  
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humans meningoencephalitis and retinitis can develop 1 to 2 weeks after onset 
of infection. In lambs the virus can also cause necrosis of villi at the distal 
jejunum and ileum and depletion of lymphocytes in the spleen, but in these 
animals the brain and eyes lesions are not frequent [Coetzer 1977].
The coagulation defects that cause formation of purpura and widespread 
haemorrhages, are due to vasculitis and necrotic hepatitis which reduces the 
production of coagulating proteins.
Recovered animals will be protected by a long life immunity.
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6. Clinical signs
6.1 Clinical signs in animals
The incubation period ranges from a few hours to a few days and is 
dependent on multiple factors, including: the inoculation dose, the virus 
strain, the route of inoculation, the age of each animal and the animal species 
[Zaho et al. 2008, Pepin et al. 2010]. There are marked differences in the 
patterns of RVF in domestic animals, varying from moderate to serious 
clinical disease. However, a sudden onset of abortions among sheep, goats, 
cattle and camels, together with high mortality in newborn animals, is 
probably the most significant sign of the presence of the disease in an area 
[Davies et al.2006].  
In sheep and goats
the clinical signs of RVF have been classified into four forms according to the 
severity of the disease. In general, goats are less severely affected than 
sheep, with much lower morbidity and mortality, and fewer abortions.
Hyperacute form. Abortion in  90%-100% of pregnant ewes and mortality of 
80%-100% in lambs under ten days of age. Most deaths are sudden and 
occur within 12 hours after the onset of pyrexia (40-42°C). Other lambs may 
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Fig 18: ewe aborting as a result of RVF [ FAO]
be too weak to suckle or stand, and die within 24-48 hours, showing only 
fever, prostration and accelerate breathing [Easterday 1962 a, Easterday 
1965].
Acute form. Older lambs, from two to three weeks of age may show severe 
clinical signs with high fever and an elevated respiratory rate, muco-purulent  
or sero-sanguineous nasal discharges, injected conjunctivae, vomiting, 
abdominal pain and generalized lymphadenitis. Animals are reluctant to 
move, become recumbent and often develop a haemorrhagic diarrhoea. 
Deaths occur after 24-48 hours with mortality rates ranging from 10% to 60%. 
Sick and recovering animals generally show moderate to severe signs of 
jaundice.
Subacute form. This is more frequent in adult animals and starts with high 
fever persisting for one to five days followed by anorexia, injected 
conjunctivae, nasal discharges, vomiting, diarrhoea and abortion.The 
mortality rates are of the order of 5%-20 %.
Inapparent form. This occurs in older or resistant animals. The animals may 
have episodes of fever, which remain usually undetected and females 
occasionally may abort. These infections are generally detected only by 
subsequent serological testing [ Daubney et al. 1931, Easterday et al. 1962, 
Easterday 1965, Tomori 1979, Davies et al.2006].
The disease in cattle resembles that in sheep, but is less severe and  a 
higher proportion of animals may develop icterus. Calves under ten days of  
age may be affected by the hyperacute form and die within 20-24 hours with 
few, if any, premonitory signs. Signs that may be observed are fever, sero-
sanguineous nasal and lachrymal discharges, and elevated respiratory rate.  
The infection is frequently inapparent in the majority of the adult susceptible 
and indigenous bovids in Africa, which are relatively resistant to RVF, but 
some animals develop the acute form showing fever , nasal and lachrymal 
discharges that may be blood-tinged, anorexia and prostration. The animals 
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may have abdominal pains and profuse fetid haemorrhagic diarrhoea that  
persists for several days. A moist cough with evidence of respiratory distress 
may be present. The superficial lymph nodes generally become enlarged and 
a drop of milk production is observed. Abortion is a frequent outcome of 
infection also in pregnant cattle. Animals commonly abort at any stage of 
gestation, however, abortion rates may be variable. Mortality rates in cattle 
varies from 10% to 40%, depending on the age and breed of the animals 
[Coetzer 1982, Paweska 2015, Davies et al.2006].
The subacute form affects older cattle. The clinical signs last for few days 
and are: fever nasal and lachrymal discharges, profuse watery diarrhoea and 
drop of milk production of lactating cows [Coetzer 1982, Davies et al.2006].
Deaths do occur in camel foals only during the early post-natal period and 
abortion is also a common consequence of the infection in this specie, but 
normally these animals show mild clinical signs and viraemia is of short 
duration [Davies et al.2006]. 
Nevertheless a field study carried out during an outbreak in 2010 in 
Mauritania documented a severe form of RVF in camels.
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Figure 19: Bovine, aborted fetus [Photo from  
Plum Island Animal Disease Center].
Two clinical forms were observed: an hyperacute form, with sudden death in 
<24 hours and an acute form with fever, ataxia, edema at the base of the 
neck, respiratory distress, blood-tinged nasal discharge, icterus, severe 
conjunctivitis with ocular discharge and blindness, haemorrhages of gums 
and tongue, foot lesions, nervous symptoms, and abortions (Fig. 20). When 
hemorrhagic signs developed, death usually occurred within a few days [El 
Mamy 2011].
43
Figure 20: clinical signs of RVF in camels. A) Conjunctivitis, ocular discharge, 
hemorrhages of the gums, and edema of the trough; B) hemorrhages of gums  
and tongue; C) foot lesions (cracks in the sole) with secondary myasis; D)  
edema at the base of the neck; E) dead camel with sign of abortion,  
convulsions, and arching of the neck [ El Mamy 2011].
Wild ruminants do not show any clinical signs of RVF during epizootics in 
domestic ruminants sharing the same grasslands. However, they develop 
antibodies to the virus and may even abort, following subclinical infections, 
even if this is difficult to demonstrate in the field. Following experimental 
inoculation, the african buffalo, Syncerus caffer, has a viraemia lasting for two 
days, and pregnant buffalo cows may abort [Davies et al. 1981, Davies et 
al.2006].
Diseases to be taken into consideration in the differential diagnosis of RVF in 
animals include: Wesselsbron disease, bluetongue, ephemeral fever, Nairobi 
sheep disease, Heartwater, peste des petits ruminants, infection by 
thogotovirus, Q fever, Foot-and-mouth disease, toxoplasmosis, brucellosis, 
salmonellosis, pasteurellosis, leptospirosis, chlamydiosis, anthrax, ingestion 
of poisonous plants [Swanepoel et al. 2004, FAO]. 
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6.2 Clinical signs in humans
Detailed studies of RVF in humans were carried out during several of the 
more recent epidemics occurred in the Arabian Peninsula and Africa [Pepin et 
al. 2010]. Most patients exhibit a self-limiting, febrile illness, however, some 
patients may develop neurological disorders,and hemorrhagic fever (Fig. 21)  
[Easterday 1965, Weiss 1957]. 
Less than 1% of human patients develop the haemorrhagic and/or 
encephalitic forms of the disease and the overall case fatality rate (CFR) is 
estimated to range from 0.5% to 2%, even if it appears to have been higher 
in recent outbreaks.
Self-limiting febrile illness
The incubation period for RVF is 4 to 6 days and the symptoms start abruptly 
with severe chills, malaise, dizziness, weakness, severe headache, nausea 
and/or sensation of fullness over the liver region [Findlay et al. 1931, Kitchen 
1934]. These symptoms are followed by: elevated body temperature (38.8 °C 
to 39.5 °C), decreased blood pressure, pain in the back, shoulders, neck, 
legs, rigor, shivering, flushed face, conjunctivitis, constipation, insomnia and 
photophobia. Occasionally, other symptoms are seen which include epistaxis,  
abdominal pain, lack of gustatory discrimination, vomiting and diarrhoea 
[Daubney et al.1931, Findlay et al. 1931, Kitchen 1934, Smithburn et al. 
1949].
Symptoms start to decrease on the 3rd day, and the body temperature often 
decreases to a normal level by the 4th day after the onset of symptoms.
After body temperature becomes normal, some patients may develop a 
massive coronary thrombosis [Mundel et al. 1951], persistent aching of legs 
for two weeks [Kitchen 1934] or persistent abdominal discomfort for weeks 
[Daubney et al.1931]. 
In the convalescence phase, patients often experience weakness, malaise, a 
tendency to sweat, frequent headaches, pain on motion of the eye, and a 
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sense of imbalance. 
Encephalitis and retinitis
This forms are severe complications of RVF, developing 1 or 2 weeks into the 
course of diseases.
Maar et al. described a case of encephalitis; the disease started with fever,  
rigor and retro-orbital headache. After a second rise of fiver, 3 weeks later,  
the patient manifested neck rigidity, confusion, mental disorder, convulsive 
attacks and temporal vision loss without detectable retinopathy. His 
cerebrospinal fluid (CSF) contained an increased number of white blood cells  
(mainly lymphocytes), indicative of viral meningitis or meningoencephalitis 
[Maar et al. 1947].
Also another studies describes encephalitis and retinitis in humans like Al-
Hazmi et al. in 2000 that analysed a total of 165 RVF patients in Saudi Arabia 
[Al-Hazmi et al. 2003] and Alrajhi et al. in 2004.
Other studies describe encephalitis and retinitis in humans: Al-Hazmi et al. in 
2000 [Al-Hazmi et al. 2003] and Alrajhi et al. in 2004.
Estimates for the incidence of ocular complications in human RVF infections 
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Fig 21: the pathological forms of RVF in humans [Ikegami et al. 2011].
range from less than 1% to 20%. The ocular disease usually is characterized 
by a loss of acuity of central vision, sometimes with development of scotomas 
[Swanepoel et al. 2011, Paweska et al. 2013], maculopathy and retinopathy 
[Ikegami et al. 2011]. The loss of visual acuity generally resolve over a period 
of months, with variable residual scarring of the retina, but in instances of  
severe haemorrhage and detachment of the retina there may be permanent  
uni-or bilateral blindness. 
Haemorrhagic form
Most typically, the illness starts suddenly, and the patients experience fever,  
rigor, nausea, vomiting, headache, injected conjunctives, drowsiness, and 
body pains. The patients may also have symptoms of macular rash over the 
entire trunk, ecchymoses on the arms, limbs, and eyelids, bleeding from the 
gums and gastrointestinal mucosal membrane, low blood pressure, 
hematemesis, melena, diarrhea, throat pain, pneumonitis, jaundice, 
hepatosplenomegaly [Yassin 1978, Swanepoel et al. 1979]. In many cases, 
death occurs in 3 to 6 days after patients become symptomatic [Swanepoel et 
al. 1979, Al-Hazmi et al. 2003, Ikegami et al. 2011].
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Figure 22: macular retinitis with  
exudates and haemorrhage in  
themacular and paramacular  
areas of a patient with RVF [Al-
Hazmi et al. 2003].
The CFR for patients developing the haemorrhagic form of the disease can 
be as high as 50% [Mohamed et al. 2010, Nguku et al. 2010].
Table 6: clinical features of patients with laboratory-confirmed RVF in 
Saudi Arabia, 2000–2001 [adapted from Madani et al. 2003].
Symptoms Number of 
patients with 
symptom.
Number of patients 
under active 
observation.
%
Fever 499 539 92.6
Nausea 315 530 59.4
Vomiting 280 532 52.6
Abdominal pain 202 532 38.0
Diarrhea 118 530 22.1
Jaundice 96 530 18.1
Neurological symptoms 81 475 17.1
Haemorrhagic form 35 494 7.1
Ocular complications 10 683 1.5
Deaths 95 683 13.9
In the differential diagnosis of RVF in humans, several diseases should be 
considered: other viral haemorrhagic diseases, malaria, Q fever, typhoid 
fever, dysentery, plague, brucellosis, leptospirosis, meningitis, sepsis from 
bacterial infections, viral hepatitis as well as non-infectious causes of 
disseminated intravascular coagulopathy and acute leukaemia [Paweska et 
al. 2013].
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7. Pathology
The hepatic lesions of RVF are essentially similar in animals and humans, 
varying mainly with the age of the affected individual [Swanepoel et al. 2004].
In young animals died during the early stage of the disease no specific lesions 
may be evident, but only signs associated with viraemia, such as widespread 
petechial and ecchymotic haemorrhages on serous surfaces and organs. In 
foetuses and new-born lambs the liver is usually moderately to greatly 
enlarged, soft, friable and yellowish-brown to dark reddish-brown in colour with 
irregular congested patches and sometimes haemorrhages of varying size 
scattered throughout the parenchyma. The necrotic lesions may be evident as 
small 1-3 mm foci, which coalesce to form larger areas of necrosis involving 
the whole liver. The necrotic changes induce jaundice and in a later stage the 
liver show a bronze appearance due to a conjunction of congestion, necrotic  
lesions and icterus (Fig.24) [Coetzer 1977, Davies et al.2006].
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Figure 24: new-born lamb liver: bronze 
appearance, congested patches,  
haemorrhages and greyish-white  
necrotic foci [Swanepoel et al. 2004].
Figure 23: new-born lamb liver: pin-point  
necrotic foci [Swanepoel et al. 2004].
There may be oedema and haemorrhages in the wall of the gall bladder and 
hepatic lymph node. Mild icterus is evident in only about 10% of affected lambs 
because of the hyperacute course of the disease  [Swanepoel et al. 2004].
Icterus may be more evident in adult sheep, even if hepatic lesions are usually  
less severe. In sheep haemorrhages and oedema of the wall of the gall 
bladder are commonly observed, the mucosa may be necrotic and ulcerated 
and the lumen may contain blood clots or blood-tinged bile (Fig.25-26). The 
spleen may or may not be enlarged, with extensive subcapsular 
haemorrhages. 
The kidneys show congestion with some petechial haemorrhages. The heart  
usually shows sub-epicardial and endocardial haemorrhages. The lungs are 
hyperaemic with sub-pleural haemorrhages and occasionally emphysema and 
oedema. The alimentary tract usually shows haemorrhagic gastro-enteritis and 
catarrhal, haemorrhagic and necrotic inflammation. The serous surface of the 
bowels may be covered with petechial and ecchymotic haemorrhages. The 
abomasum may contain digested blood. The peripheral and visceral lymph 
nodes are enlarged oedematous and haemorrhagic [Coetzer 1977, Swanepoel 
et al. 2004, Davies et al.2006].
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Figure 25: adult sheep gall bladder:  
blood-tinged bile [Swanepoel et al. 2004].
Figure 26: adult sheep gall bladder:  
blood coagulum [Swanepoel et al. 2004].
The livers of aborted calf foetuses and adult cattle resemble those of adult  
sheep and the lesions of new-born calves are very similar to those in neonate 
lambs [Daubney et al. 1931, Coetzer 1977]. Accentuation of the lobulation is 
often evident in the livers of these animals, in addition, the gall bladder wall is  
frequently oedematous and haemorrhagic. The spleen is normal in size or  
slightly to moderately enlarged and congested. The lymph nodes are swollen 
and oedematous and show petechial haemorrhages in the cortex and medulla.  
Other lesions included: congestion and oedema of the lungs; haemorrhages 
on the surface of various organs (spleen, heart, rumen, small and large 
intestine) (Fig.27-28); oedema of the abomasal folds accompanied by mucosal  
haemorrhages and copious amounts of fresh or partially digested blood in the 
lumen of the abomasum, the small intestine and sometimes also in the large 
intestine [Coetzer 1982].
 
Hepatic necrosis is the most characteristic microscopic finding in all domestic 
ruminants. A massive necrosis of the liver parenchyma is observed, with 
haemorrhage and infiltration of lymphocytes, polymorphonuclear leukocytes 
and histocytes. Changes include cloudy swelling followed by hyaline 
degeneration. The result is that the original architecture of the liver is often 
unrecognisable [Easterday et al.1962 a, Coetzer 1977, Coetzer 1982]. 
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Figure 27: bovine spleen: capsular  
haemorrhages [Swanepoel et al. 2004].
Figure 28: bovine intestine: petechial  
haemorrhages in the serosa of the large  
intestines [Swanepoel et al. 2004].
Encephalitis, commonly seen as a serious complication of human cases, may 
occur in a very small proportion of RVF infected ruminants showing 
abnormalities in movement and posture.
Studies in calves indicate that, following viral replication, necrotizing 
encephalitis with diffuse perivascular infiltrates of lymphocytes and 
macrophages occur in cerebral parenchyma [Anderson et al.1988, Rippy et al.  
1992]. Postmortem histopathologic examination of infected rhesus monkeys 
brains has shown a mild, non-suppurative, multifocal, perivascular encephalitis  
in the cerebral cortex and nodular aggregates of neutrophils associated with 
mild necrotic changes of neurons [Morrill et al.1990].
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Figure 29: adult sheep liver: focal area of  
necrosis [Swanepoel et al. 2004].
Figure 30: calf liver: multifocal hepatic  
necrosis [Paweska, 2015]. 
8. Laboratory diagnosis
There are health and safety issues to be addressed when considering the 
clinical and laboratory diagnosis of RVF because the virus presents a high bio-
hazard risk for laboratory personnel [Paweska, 2015].
Work with RVFV requires high biocontainment facilities and well trained 
laboratory staff, furthermore the virus is considered a potential bioweapon 
agent. The current capacity for laboratory diagnosis of RVF is restricted to a 
limited number of reference laboratories worldwide [Pepin et al.  2010].
Diagnosis of RVF is achieved using various techniques, including virus 
isolation [Anderson et al.1989] antigen detection [Niklasson et al. 1983, 
Meegan et al.1989] nucleic acid amplification techniques [Ibrahim et al.1997, 
Garcia et al.2001, Drosten et al. 2002] and by detection of specific antibodies 
[Swanepoel et al.1986 b].
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8.1 Virological diagnosis
Samples for virological diagnosis can be:
• heparinized blood, plasma or serum collected 
from live animals during the febrile stage of the 
disease,
• tissue samples of liver, spleen, kidney, lymph 
node, heart blood and brain collected from dead 
animals and aborted foetuses [Gerdes 2004].
Samples should be kept at 0–4°C during transit 
and if transport to the laboratory is likely to take 
more than 24 hours, should be frozen and sent on 
dry ice or frozen cold pack. Blood sample and 
plasma should be collected and frozen for 
transport [Gerdes 2004 b].
RVFV can be isolated in a variety of cell cultures, both primary (calf and lamb 
kidney and testis cells) and cell lines (Vero, BHK21, and some mosquito cell  
lines). Cytopathic effect may be observed from one to five days after 
inoculation of cell cultures. Alternatively isolation can be made through mice 
inoculated intra-cerebrally or intra-peritoneally [Swanepoel et al. 2004].
Immuno-histopathological examination of affected animals liver will reveal 
characteristic cytopathology and specific identification of RVF viral antigen in 
tissue [Coetzer, 1982 b]. This technique is an important diagnostic tool 
because tissues are placed in neutral buffered formaldehyde in the field and 
therefore do not require a cold chain during transport from remote areas and 
furthermore samples can be handled safely due to the inactivation of the 
virus [OIE, 2014].
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Figure 31: blood 
sampling in Mikum,  
Tanzania.
Virus antigens can be detected by immunofluorescence (IF) test on 
impression smears of tissues of dead animals and foetuses and in infected 
cultures, before the appearance of cytopathic effect (CPE), as early as 24 
hours after inoculation (Fig.32) [Gerdes 2004 b].
An other technique for the antigen detection is an enzyme-linked 
immunosorbent assay (Ag-ELISA). This test is ideal to detect the virus in 
aborted foetuses and organs [Pepin et al. 2010]. For safety reasons samples 
should be inactivated by detergents or heat [van Vuren et al. 2009]. 
Sensitivity and specificity of Ag-ELISA range from 67.7% and 70%, and 
97.97% and 100%, respectively. The assay is able to detect nucleoprotein 
antigen in infected culture supernatants 12 to 30 h before the appearance of  
CPE, permitting the rapid identification of the virus during primary isolation 
[Pepin et al. 2010]. The Ag-ELISA represents a valuable diagnostic tool for 
laboratories in Africa and for routine differential diagnosis with other viral  
haemorrhagic diseases [van Vuren et al.2009].
Diagnosis can also be made by detection of viral RNA by PCR techniques 
(conventional RT-PCR and real-time PCR) [Ibrahim et al. 1997, Garcia et al. 
2001]. This techniques can be used to detect the viral genome both in 
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Figure 32: RVF virus antigen in cell cultures 24 hours  
post inoculation with specimens for diagnosis [FAO].
animals samples and mosquito pools [Ibrahim et al. 1997].
During the 2006 RVF outbreaks in Kenya, real-time PCR was evaluated to 
identify patients with high viraemia, thereby enabling them to be targeted for  
special or intensive clinical management [Njenga et al.2009]. This was the 
first report of this technique being used for case-confirmation. The nucleic 
acid detection assays in humans should be run in parallel with additional 
tests, including detection of type-specific antibodies to RVFV. In this context it 
is important to note that viraemia in RVFV-infected individuals is of very short 
duration and most infected patients and adult ruminants undergo subclinical  
or mild infections; however, IgM and IgG antibodies are easily demonstrable 
shortly after exposure to the virus [Paweska et al. 2005, Pepin et al. 2010].
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8.2 Serological diagnosis
The classical methods for the detection of antibodies to RVFV include 
haemagglutination-inhibition, complement fixation, indirect 
immunofluorescence and virus neutralization tests (VNT) [Swanepoel et al. 
1986 b, Gerdes 2004 b]. The disadvantages of these techniques include 
health risks to laboratory personnel and restrictions for their use outside RVF 
endemic areas [Kitchen 1934, Smithburn et al. 1949, Van Velden et al. 1977]. 
As described in the OIE “Manual of Diagnostic Tests and Vaccines
for Terrestrial Animals 2015” virus neutralisation is the prescribed test for 
international trade. The VNT test may be used to determine the presence of  
antibodies in naturally infected animals and in vaccinated animals. The test is 
highly specific and can be used to test serum of any species. It is generally 
used to measure vaccine efficacy. Although regarded as the gold standard, 
the VNT is laborious, expensive and requires 5–7 days for completion. 
Various ELISA formats developed in recent years for the specific detection of 
IgG, IgM or total antibodies, were shown to be highly accurate diagnostic 
tools in disease surveillance and control programs, import/export veterinary 
certification and for monitoring the immune response of vaccines [Paweska et 
al. 2005, Cetre–Sossah et al. 2009]. The dynamics of virological, IgM and 
IgG responses in a sheep experimentally infected with a wild strain of RVFV 
(J.T. Paweska, unpublished data) are shown in Fig. 33.
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Figure 33: Duration of viraemia, and IgM and IgG responses in a sheep  
experimentally infected with RVFV [Paweska, 2015].
9. Prevention and control
Prevention and control of RVF is achieved by a combination of vaccination and 
sanitary measures.
9.1 Vaccine and vaccination
Vaccination is the most effective way to protect animals. For this purpose 
have been used both attenuated and inactivated vaccines.
The most common attenuated vaccine used in Africa is Smithburn vaccine, 
based on an attenuate RVFV strain which has only partially lost its virulence. 
Its use is restricted during devastating outbreaks and only in non-pregnant  
females [Barnard 1979, Swanepoel et al. 2004] as it induced abortions and 
teratogenesis in ewes, cows and goats [Botros et al.2006, Swanepoel et al. 
2004, Kamal 2009].
An inactivated vaccine has been produced to circumvent these difficulties, 
but this is not efficacious as the attenuated vaccines and needs booster 
inoculations (Tab. 7) [Barnard et al.1977]. 
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Table 7: properties of live-attenuated and inactivate animal vaccines against  
RVF [Pepin et al.2010] .
Live-attenuated vaccine Inactivated vaccine
Origin/Production •Derived from the Smithburn 
strain
•Attenuated by successive 
intracranial passages in 
newborn mice and in 
embryonated eggs (resulting 
in a neurotropic strain); 
produced in cell culture since 
1971
•Derived from South African field 
strain
•Inactivation with formaldehyde
•Contains adjuvant
Advantages • Needs only one injection 
•Long duration of protective 
immunity (entire economic life 
of animals)
•Inexpensive
•No adverse effects 
•No contraindications
Limitations •May induce abortions and 
fœtal malformations,
•Not for use in pregnant 
animals 
•Transient viraemia
•Possible residual human 
pathogenicity 
•Possible reassortment with 
field wild–type strains
•Need two injections during the 
first year and booster doses 
annually
•Short duration of protective 
immunity
•Expensive
Recommendati
ons for vaccine 
use
•Used in countries/regions 
where the RVF is enzootic
•Before the reproductive 
season
•Used in countries/ regions
 newly infected or free, but at risk
Common 
properties
•Do not allow the differentiation 
of vaccinated and naturally-
infected animals ( no « DIVAª 
strategy »)  
•Age of vaccination: > 6 month 
ª DIVA = ‘‘Differentiation of infected and vaccinated animals’’.
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After the Egyptian outbreaks in 1977 was produced a new attenuated 
vaccine, called MP12, obtained from the virulent Egyptian strain (ZH548) 
after random mutagenesis with 5-fluorouracil [Caplen et al.1985]. As a 
consequence of acquired mutations in all three segments, the virus resulted 
avirulent in mice [Saluzzo et al. 1990], and was able to induce a good 
immunity in ruminants after experimental inoculation [Morrill et al. 1997]. 
However, Hunter et al. in South Africa have demonstrated that MP12 was still 
able to cause abortions and teratogenesis during the early stages of 
pregnancy [Hunter et al.2001].
Another attenuated vaccine is Clone13, derived from an attenuated strain 
with a large deletion in the S segment of the gene segment coding for non 
structural proteins [Muller et al. 1995].
In the study carried out by Von Teichman et al., Smithburn vaccine and 
Clone13 vaccine were compared for safety and efficacy in young calves. 
Protection was confirmed by a good neutralizing antibody response in all the 
animals of both vaccinated groups and no viraemia and clinical signs of RVF 
were observed [Von Teichman et al. 2011].
Clone13 vaccine, tested in sheep, does not cause acute local or systemic 
reactions, not spread to in contact animals and not revert to virulence. It has 
favourable properties for use in lambs, however, in pregnant animals,  
especially during the first trimester of pregnancy, Clone13 may infect the 
foetus and cause malformations and stillbirths [Makoschey et al. 2016].
A recombinant vaccine based on replication-deficient chimpanzee adenovirus 
(ChAdOx1) was described by Warimwe et al. in 2016.
A single-dose of the vaccine ChAdOx1-GnGc, composed of ChAdOx1, 
[Antrobus et al.2014], with the insertion of RVFV envelope glycoproteins (Gn 
and Gc) genes, leads to the production of high-titres of neutralizing antibody,  
comparable to those following vaccination with Smithburn vaccine. This 
vaccine confers protection in mice [Warimwe et al.2013], in sheep, goats and 
cattle and induce neutralizing antibody response in dromedary camels even if  
has not yet been determined the protective efficacy in this specie. Further 
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studies will evaluate ChAdOx1-GnGc protective properties to humans in 
clinical trials [Warimwe et al.2016]. 
At the moment immunisation of professionals at high risk of infection is 
performed on a voluntary basis through the use of an experimental  
inactivated RVF vaccine [Rusnak et al. 2011].
9.2 Sanitary measures
Restriction of livestock movements is an important measure in slowing the 
spread of the virus from infected to uninfected areas.    
Vector control measures may have some efficacy in reducing the risk of RVF. 
This control can be achieved by:
– strategic larvicidal treatment of mosquito breeding habitats by means of 
hormonal inhibitors (methoprene) and larvicidal toxins (produced by Bacillus 
thurigiensis),
– reduction of mosquitoes reproduction changing the breeding habitat,  
– use of insecticides active on adult mosquitoes,
– use of insect repellents on animals,
– use of mosquito nets in stables and barns [Anyamba et al. 2009, Davies et 
al. 2006 ].
All these measures are difficult to apply and in some cases are not 
efficacious and contribute to environmental contamination.  
In affected areas also is important personal and community protection against  
vectors bites. People can protect themselves using impregnated mosquito 
nets and personal insect repellent, wearing light-coloured clothing, long-
sleeved shirts and trousers, and avoiding outdoor activity, especially at peak 
biting times of mosquitoes. Healthcare workers caring for patients with 
suspected or confirmed RVF should implement standard precautions 
thoroughly. Samples taken from suspected human and animal cases of RVF 
for diagnosis should be handled by trained staff and processed in suitably 
equipped laboratories [Paweska 2015]. 
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During an outbreak of RVF, close contact with animals, particularly with their 
tissues and body fluids, either directly or indirectly, is the most important risk 
factor. Therefore, in the absence of specific treatment and of effective human 
vaccine, raising awareness of the risk factors of RVF infection is the only 
practical way to reduce human infection and deaths. Public health messages 
should focus on reducing the risk of animal-to-human transmission as a result  
of unsafe animal husbandry and slaughtering practices. Appropriate 
protective clothing should be worn and care taken when handling sick 
animals or their tissues or when slaughtering animals. In the affected regions,  
all animal products should be heat processed before eating [Swanepoel et al.  
2011]. 
9.3  Surveillance and early warning system
An active animal health surveillance system to detect new cases is essential 
in providing early warning. Detecting animal cases during the early stages of  
an outbreak and sharing information between veterinary and public health 
services is critical to implement timely control measures. 
RVF is one of the diseases for which early warning systems have been 
developed efficiently. These systems have shown potential and relevance in 
anticipating outbreaks and mitigating the consequences.
Forecasting models using satellite images and weather/climate prediction 
data are useful for signalling increased risk of RVF outbreaks [Swanepoel et  
al. 2004, 2011, Gerdes 2004 c]. 
Early warning systems are based on a combination of local surveillance 
activities associated with the monitoring of different types of climate data, 
including three-month seasonal weather forecasts, near-real-time rainfall,  
Normalized Difference Vegetation Index (NDVI) estimates and El Niño/ 
Southern Oscillation (ENSO) indicators [Anyamba et al. 2009, Linthicum et al. 
2007].
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The areas with persistent positive rainfall anomalies represent suitable 
habitats for RVFV vectors, so the countries where this above-average rainfall  
anomalies are expected should stay on alert.
The connection between precipitation and RVF outbreaks was described by 
Davies et al. in 1985 analysing the rainfall records from 1950 to 1982 and 
showing the association between epizootics and positive surplus rainfall  
(Fig.34) [Davies et al. 1985].
The use of rainfall and NDVI data from satellite images in East Africa allowed 
in several cases to implement enhanced surveillance activities for animals 
and humans before the identification of the first RVF outbreaks [Anyamba et 
al., 2009].
The study by El Mamy et al. in Mauritania.associated RVF outbreaks with 
exceptionally heavy rainfall. A rainfall surplus caused an unusual growth of 
vegetation, increasing the number of ruminants hosts, and favouring high 
densities of mosquitoes. The presence of many competent vectors and 
available hosts, resulted in severe outbreaks of malaria and RVF in several 
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Figure 34: relationship between RVF epizootics and rainfall in Kenya for the years  
1951-82 [Davies et al. 1985].
oases of the Adrar region [El Mamy et al. 2011].
In order to prevent possible RVF outbreaks it is important to study the inter 
annual climate variability associated with the ENSO phenomenon . ENSO is 
exemplified by extensive warming of the normally cold waters of the central  
and eastern Pacific Ocean and a cooling in the western Pacific Ocean 
(Fig.35). El Niño (EN) is the term used to describe this periodic warming. 
These changes leads to anomalous climatic conditions, in particular dramatic  
shifts in precipitation patterns that can result in the onset of mosquito-borne 
disease outbreaks [Anyamba et al. 2001, 2012]. 
Generally, RVF outbreaks followed a period of 3–4 months of persistent and 
above-normal rainfall that enabled vector habitats to flourish [Anyamba et al.  
2012].
The monitoring of climate data have to be combined with local surveillance 
activities.
• Surveillance in sentinel herds: small herds of susceptible ruminants 
located in geographically representative areas (near rivers, swamps 
and dams) may give epidemiological information on RVF exposure. 
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Figure 35: December 1997 — February 1998 sea surface temperature (SST) anomalies 
during the peak of the 1997/98 warm ENSO event [United States Department of  
Agriculture,Agricultural Research Service].
This kind of surveillance is important to detect increased virus activity 
or build-up in competent vectors in order to establish baseline 
information on inter-epidemic virus transmission patterns.
• Surveillance in slaughterhouses and markets: this places can be used 
as sources of information on RVF viral circulation, especially when the 
origins of animals slaughtered and traded can be traced back.
• Syndromic surveillance: any suspected case in animals and in 
particular higher than expected numbers of abortions and neonatal  
mortalities, should be reported immediately [Anyamba et al., 2009].
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10.Risk of RVF introduction into Europe
RVFV has proven to be very sensitive to climate and socio-economic changes. 
This fact, in association with: the expansion of RVF to Arabian peninsula and 
north Africa, the growth of human population, the increase of livestock trade, 
has increased the risk of introduction of RVFV in the Middle East, 
Mediterranean basin and south Europe [Chevalier et al. 2010].
The risk of RVF introduction and persistence in Europe has been examined by 
the EFSA Scientific Panel on Animal Health and Welfare.
The following routes of entry have been considered: importation of live animals  
and animal products via both legal and illegal routes and introduction by 
infected vectors, infected humans,contaminated materials and attenuated 
vaccines.
10.1 Probability of introduction through live animals
The importation of infected ruminants and their products may be a risk factor  
for RVF introduction, for this reason official RVF-free status is required to 
export livestock and animals products into the EU [Chevalier et al. 2010].
A country is considered RVF free when the disease is notifiable in the country 
and either:
• the country lies outside and is not adjacent to the historically infected 
regions;
• a surveillance programme has demonstrated no evidence of infection in 
humans, animals and mosquitoes in the country during the past 4 years 
following a RVF epidemic. 
Council Decision 79/542/EEC lists countries approved for imports of live 
animals and fresh meat of bovine, caprine, ovine and porcine species into the 
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EU and establish the animal health requirements:
• the exporting country (or region) must have been free of RVF during the last  
12 months with no vaccination against RVF and no imports of domestic 
cloven-hoofed animals vaccinated against this disease;
• animals have remained on the territory since birth, or for at least the last 6 
months, for breeding and productive animals and 3 months for slaughter 
animals and without contact with imported cloven hoofed animals for the last  
30 days.
This means that currently cattle, sheep, goats and pigs can only be imported 
from very few countries, none of which belong to the African continent and 
Arabian peninsula where RVF is endemic. 
Council Decision 79/542/EEC does not cover imports of non-domesticated 
animals for shows or exhibitions where such animals are not regularly kept or  
bred, and those non-domesticated animals forming part of circuses, zoos, or  
intended for scientific including conservation or experimental purposes.
The risk of introduction of RVFV through movement of infected animals is 
mainly due to illegally imported animals [EFSA 2013].
The illegal importation of millions of sheep and goats from Africa to the 
Middle East for ritual slaughter is a potential route of circulation of RVFV 
[Davies F.G. 2006].
We presume that some illegal ruminant importations may occur between the 
Middle East and central Europe and between northern Africa and southern 
Europe [Chevalier et al. 2010].
In conclusion the probability of RVF introduction with legal animals 
importation is currently assessed as low, although not negligible. The 
probability of importation of RVF infected zoo animals is likely to be higher if it  
occurs during RVF outbreaks in the source country.
While the risk of RVF introduction by illegal import of animals is estimated to 
be between negligible to low, but it can increase during epidemic periods and 
is higher in small ruminants compared to cattle.
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10.2 Probability of introduction through animal products
Animal products include meat (fresh and processed), milk (fresh, pasteurised 
and processed), hides and wool.
The majority of legally imported animal product is frozen for export soon after  
slaughter, so the majority of any viable virus present would survive until  
thawing.
The study performed by Adkin et al., describes the risk assessment for Great 
Britain due to illegal importation of ruminant and porcine product. It has been 
estimated that only a small fraction of attempted illegal imports of meat 
products may be detected (approximately between 0.01% and 1%) and the 
total quantity illegally imported per year was estimated to be between 4,300 
and 28,600 tonnes [Adkin et al. 2004].
Wool is not considered infected, hides are subjected to salting and imported 
milk is unlikely to contain viable virus after pasteurization.
In conclusion the risk of RVF legal import by animals products is negligible 
for small ruminants and low for cattle.
The probability of introduction of the virus with illegally imported animal 
products is higher than negligible and under conditions of high viral activity 
may even be moderate to high.
10.3 Probability of introduction through infected vectors
The maximum distance flown actively by mosquitoes is usually between 1 
and 5 km. Translocation of insects over long distances is mainly passive and 
may be associated with various types of transportation (e.g. ships, trains, 
aeroplane, lorries) or wind [Service 1997, Reynolds et al. 2006].
During epidemic periods the prevalence of RVF infection in vectors may be 
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high, while negligible during inter-epidemic periods. During periods of intense 
virus activity in Egypt and Arabian peninsula, infected vectors could be 
carried by winds into Turkey, Cyprus and other Mediterranean countries with 
a probability between high and moderate.
Long-distance wind-borne transportation has already happened in the past  
and probably contributed to the spread of RVFV into Egypt from Sudan 
[Sellers et al.1982]. This phenomenon also happened with other diseases 
like Bluetongue [Sellers et al. 1978] and African horse sickness.
The probability of infected vectors entering by ships, trains, containers is 
negligible, but this may increase during periods of high viral activity unless 
specific safety measures are taken.
10.4 Probability of introduction through infected humans
Humans are generally considered to be dead-end hosts for RVFV, with 
negligible capacity to transmit the virus and to amplify transmission 
[Chevalier et al.2010].
However, several recent studies suggested that humans and international air  
travel may play a role in disease dispersal [Pfeffer et al. 2010 ]. The number 
of confirmed cases of international travellers infected with RVFV is low 
(several members of the French military troupe [Durand et al.2002], a 53 
year-old woman in France and a 54 year-old man in the United Kingdom 
[ECDC 2014]).
Considering that the viraemia in humans is short and that the disease may be 
subclinical, the risk is related to the level of viral activity in the source country 
and therefore is considered negligible during inter-epidemic periods and low 
in the epidemic ones.
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10.5 Probability of introduction through contaminated fomites
Exposure of fomites to RVFV(e.g. shoes, cars , tyres etc) is associated with 
human movement into an infected area, and linked to occupational factors.
Considering the lability of the virus in the environment, the risk to transport  
the virus into Europe is to be estimated between negligible and low.
10.6 Probability of introduction through vaccines
IIntroduction of RVF through importation of RVF live attenuated vaccines, 
vaccinated animals or through a laboratory escape is theoretically possible,  
however it is never been reported.
Within the EU it is prohibited the production, marketing and administration of  
RVF vaccines, so the risk of importing the virus by these means is negligible.
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Table 8: Summary of probability of RVF introduction into Europe [EFSA 
2005, modified].
Method of entry of viable 
virus into the EU
Assessed probability of entry
Infected live animals 
legally imported
Sheep and goats: negligible,
cattle: low, not negligible: increases during epidemic 
periods in source country, 
zoo and circus animals: greater than negligible.
Infected live animals 
illegally imported
negligible to low, increases during epidemic periods 
in source country.
Contaminated animal 
products legally imported
Sheep and goat products: negligible,
cattle products: low, increases during epidemic 
periods in source country.
Contaminated animal 
products illegally imported
Moderate to high: increases during epidemic periods 
in source country.
Infected vectors Negligible during inter-epidemic periods; low to 
moderate during epidemic periods in source country.
Infected humans Negligible during inter-epidemic periods; very low 
during epidemic periods in source country.
Contaminated fomites Negligible during inter-epidemic periods; low during 
epidemic periods in source country.
Vaccines, vaccinated 
animals and laboratory 
escape 
Negligible
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10.7 Probability of RVF spread and persistence in Europe
For RVF to become endemic, the virus must be capable to spread in the 
ruminant host population. Other factors include the size of the host 
population, which needs to be large enough to increase the virus capacity to 
spread and survive [EFSA 2013].
Fischer et al. developed a transmission model to determine the initial  
epidemic growth rate of RVFV infections, following introduction of the virus. 
This allowed the creation of maps of the Mediterranean Basin and the rest of  
Europe, showing the areas at risk of RVFV spread (Fig.36).
This model was assessed using parameters for host, vector and virus using 
predicted abundances of Cx. Pipiens. Because of a lack of information on the 
seasonality of vector abundance, persistence of the virus during the 
unfavourable period with limited or no vector activity could not be assessed 
[Fischer et al.2012].
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Figure 36: risk that the threshold for spread of RVFV is exceeded  
following introduction in August with Cx. pipiens as sole vector, biting only  
susceptible hosts [Fischer et al.2012]
The factors that influence the probability of spread and persistence of RVFV 
in Europe are:
1. livestock species density and location, their proximity to points of entry 
(e.g. border inspection posts, probable illegal entry points, probable 
vector entry routes) and their susceptibility (Fig. 37),
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Figure 37: Geographical distribution of cattle and small ruminants 
[FAOSTAT].
2. presence of competent vectors; species, density and location (Tab.5) 
and their probability of infection,
3. environmental effect and climatic factors, including climatic changes, on 
the density, activity and longevity of competent vectors, both those 
native to the Europe and those which enter from outside,
4. location and biosecurity measures in force in research, diagnostic and 
vaccine production laboratories storing or handling RVFV,
5. Destination of imported livestock and probability of direct contact with 
European livestock,
6. livestock and vectors potential exposure pathways to viable virus which 
is contaminating animal products or fomites and the probability of virus 
remaining viable throughout this process,
7. intra-community movements of infected livestock.
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Figure 39: presence of Aedes vexans. Figure 40:  probability of environmental  suitability for Aedes vexans.
10.8 Surveillance systems in EU
Rift valley fever is a notifiable disease to the World Organisation for Animal 
Health (OIE).
In the majority of EU countries the surveillance is compulsory, mostly passive, 
data collection is case based at national level. 
76
11. Conclusion and perspectives
During the last decades and particularly in recent years the importance of RVF 
has been increasing.
The climate change [Martin et al. 2008], the presence of competent vectors in 
RVF-free temperate countries [Moutallier et al. 2008] and the known potential 
of RVFV to spread to uninfected areas [Fischer et al. 2012], suggests that 
RVFV should be included among the most significant emerging viral threats to 
public and veterinary health.
Recent studies have contributed greatly to understand the epidemiology of the 
disease.
In Kenya was developed a model to identify 
the geographic areas at risk, on the base of 
ecological interaction involving host animals, 
vectors, the virus and the environment.
This model can predict monthly RVF risk and 
can permit to implement effective control 
strategies, minimising the cost of surveillance 
over large areas.
This risk model made possible the early 
detection of many RVF outbreaks in 1997-
1998 and in 2006 in East Africa [Linthicum et 
al. 1999-2007, Chevalier et al. 2010].
This is potentially an important tool also for international organisations involved 
in the prevention and control of the disease in animals and humans.
United States have already applied this African model to developed an early-
warning system.
Concerning Europe the main measure to be undertaken will be:
• to set up an early-warning surveillance systems which incorporate 
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Figure 40: RVF risk map,  
December 1997 to February  
1998 [Linthicum et al.2007]
surveillance data information from RVF endemic countries as well as 
from models to predict RVFV introduction and spread, in order to detect 
suspected cases particularly in southern European countries and during 
periods favourable for the presence of vectors;
• to develop an emergency plan with a list of measures to be taken in 
case of an alert;
• to support research on new-generation vaccines, both for humans and 
animals;
• to carry out research programmes to better characterise the biology of 
RVFV potential vectors in European contest;
• to support the implementation of appropriate surveillance systems for 
early detection of RVF in livestock populations in endemic countries;
• to promote risk analyses that rely on accurate estimations of livestock 
movements between endemic and RVF-free areas;
• to update the maps of European risk areas, based on presence of 
susceptible animals, location and environmental data. This maps, 
associated with climate data, would allow the prediction of the most 
favourable conditions for the vector's breeding and for the virus 
transmission;
• to establish sentinel herds in the high risk areas in order to control 
constantly the epidemiological situation, being the greatest hazards for 
Europe the introduction of infected vectors and the local onset of 
undetected outbreaks. These sentinel herds could be used also for the 
control of other African viral diseases (Akabane virus, Lumpy Skin 
disease, Ephemeral fever etc);
• to update the capacity of European reference laboratories to be able to 
deal with diagnostic requirements during outbreak situation;
• to train veterinarians and physicians to detect RVF outbreaks as soon as 
possible.
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It could be important to highlights that the epidemiological studies, the 
implementation of surveillance systems and the measures undertaken in order 
to prevent and control RVF could be useful to prevent and control other 
diseases. In particular pathogens  that share identical epidemiological pattern 
as other emerging arbovirus that could be a threat for mediterranean 
countries. Many arboviruses are zoonotic disease . In this view it is important 
implement the new concept, "One World, One Health", indicating the close link 
between animal diseases and public health. It has long been known that 60% 
of known human infectious diseases have their source in animals (whether 
domestic or wild). Moreover the unprecedented flow of commodities and 
people gives pathogens of all kinds the opportunity to spread and multiply 
around the world, and that climate change can enable them to extend their  
range, notably through vectors such as insects colonising new areas that up 
until a few years ago were too cold for them to survive the winter.
The only way to prevent all these new hazards is to adapt the existing systems 
of health governance at world, regional and national levels in a harmonised 
and coordinated manner.
It is desirable that the discussions currently taking place on the concept "One 
World, One Health" will eventually lead all countries to give a firm commitment 
to making their animal health situation transparent and setting up mechanisms 
for the early detection of disease outbreaks. This will require a sound legal 
basis and national investments, enabling countries to achieve compliance with 
standards of quality, especially as regards their Veterinary Services, with the 
support of the whole scientific community, international organisms as OIE, 
government and, where necessary, interested international donors agencies.
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